| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-10-20 | LEE011 (ribociclib) | advanced breast cancer | 3b | Novartis (Switzerland) | Cancer - Oncology |
| 2016-10-20 | sofosbuvir, velpatasvir (GS-5816) and voxilaprevir (GS-9857) | genotype 1-6 chronic hepatitis C virus (HCV) infection | 3 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2016-10-20 | Xgeva® (denosumab) | skeletal-related event (SRE) in patients with multiple myeloma | 3 | Amgen (USA - CA) Daiichi Sankyo (Japan) | Cancer - Oncology - Bone diseases |
| 2016-10-20 | Xgeva® (denosumab) | skeletal-related event (SRE) in patients with multiple myeloma | 3 | Amgen (USA - CA) Daiichi Sankyo (Japan) | Cancer - Oncology - Bone diseases |
| 2016-10-19 | ganaxolone i | status epilepticus | 1 | Marinus Pharmaceuticals (USA - PA) | Rare diseases - CNS diseases - Neurological diseases |
| 2016-10-19 | remimazolam | procedural sedation in patients undergoing colonoscopy | 3 | Paion (Germany) | CNS diseases |
| 2016-10-19 | small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) | Curis (USA - MA) | Cancer - Oncology | ||
| 2016-10-19 | small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) | Curis (USA - MA) | Cancer - Oncology | ||
| 2016-10-18 | GED-0301 (mongersen) | Crohn disease | 1 | Celgene (USA - NJ) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2016-10-18 | tirasemtiv | amyotrophic lateral sclerosis (ALS) | 3 | Cytokinetics (USA - CA) | Neurodegenerative diseases - Rare diseases |
| 2016-10-16 | lorlatinib (PF-06463922) | ALK-positive non small cell lung cancer (NSCLC) and ROS1-positive NSCLC | 2 | Pfizer (USA - NY) | Cancer - Oncology |
| 2016-10-16 | Raxone® | Duchenne muscular dystrophy (DMD) | 3 | Santhera Pharmaceuticals (Switzerland) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2016-10-15 | abicipar pegol (anti-VEGF DARPin - AGN-150998/MP0112) | diabetic macular edema | 2 | Molecular Partners (Switzerland) Allergan (Ireland) | Ophtalmological diseases - Metabolic diseases |
| 2016-10-13 | ublituximab and ibrutinib | chronic lymphocytic leukemia | 3 | TG Therapeutics (USA - NY) | Cancer - Oncology |
| 2016-10-13 | custirsen | non-small cell lung cancer (NSCLC) | 3 | OncoGenex Pharmaceuticals (USA - WA) | Cancer - Oncology |
| 2016-10-13 | CicloMulsion® (Cremophor®-free intravenous cyclosporine formulation) | acute kidney injury | 2 | NeuroVive Pharmaceutical (Sweden) | Kidney diseases - Renal diseases |
| 2016-10-12 | PBI-4050 - 3-pentylbenzenacetic acid sodium salt | Alström syndrome | 2 | ProMetic Life Sciences (Canada) | Rare diseases - Genetic diseases |
| 2016-10-12 | ADC-1013/JNJ-64457107 | advanced stage solid tumors | 1 | Janssen Research & Development, a J&J company (USA - NJ) Alligator Bioscience (Sweden) | Cancer - Oncology |
| 2016-10-11 | Onivyde™ (MM-398 - nanoliposomal irinotecan injection) | metastatic pancreatic cancer | 3 | Merrimack Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2016-10-11 | quizartinib (AC220) | acute myeloid leukemia | 3 | Daiichi Sankyo (Japan) | Cancer - Oncology |
